Pirfenidone for artery scarring in Takayasu arteritis
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial tests whether pirfenidone, a medication used for lung scarring, can reduce scarring (fibrosis) in the arteries of people with Takayasu arteritis. It aims to slow disease progression and improve blood vessel health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Takayasu arteritis and be between 18 and 60 years old.
- Your current treatment must include both steroids and methotrexate, and you must have been on a stable dose for at least 3 months.
- You must have imaging evidence of artery wall thickening, narrowing, or new symptoms like pulse loss or blood pressure differences.
- You cannot have other autoimmune diseases (like lupus or rheumatoid arthritis) or have taken certain medications recently.
- You must be willing to avoid specific drugs that interact with the study medication (like some antibiotics, antifungals, or heart medications).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
This trial tests a medication called secukinumab for people with active, severe Takayasu arteritis, a disease that causes inflammation in large blood vessels. The goal is to see if secukinumab can help control the disease better than standard treatments alone.
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
This study tests two new medications, vunakizumab and ivarmacitinib, for people with active Takayasu's arteritis (TAK) that is not fully controlled by standard treatments. The goal is to see if these drugs are safe and effective for reducing disease activity.
Hear when a new Takayasu Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.